Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Article

In vivo emergence of cefiderocol and ceftazidime/avibactam cross-resistance in KPC-producing Klebsiella pneumoniae following ceftazidime/avibactam -based therapies

21 May 2024

Abstract excerpt

We described the emergence of ceftazidime/avibactam and cefiderocol cross-resistance in patients with KPC-producing Klebsiella pneumoniae infections. All strains with ceftazidime/avibactam and cefiderocol cross-resistance showed point mutations on KPC Ω-loop. Taken together, our results indicate that prolonged exposure to ceftazidime/avibactam can confer cross-resistance to ceftazidime/avibactam and cefiderocol.

Source

Identifiers

PMID: 38875893
DOI: 10.1016/j.diagmicrobio.2024.116372

Provenance

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In vivo emergence of cefiderocol and ceftazidime/avibactam cross-resistance in KPC-producing Klebsiella pneumoniae following ceftazidime/avibactam -based therapiesPMID 38875893Read ↗

Emergence of ceftazidime-avibactam resistance due to a novel blaKPC-2 mutation during treatment of carbapenem-resistant Klebsiella pneumoniae infections.Semantic proximity Read ↗

A large-scale surveillance revealed that KPC variants mediated ceftazidime-avibactam resistance in clinically isolated Klebsiella pneumoniae.Semantic proximity Read ↗

In vivo development of resistance to novel β-lactam/β-lactamase inhibitor combinations in KPC-producing Klebsiella pneumoniae infections: a case seriesSemantic proximity Read ↗

Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne blaKPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections.Semantic proximity Read ↗

Reduced Ceftazidime-Avibactam Susceptibility in KPC-Producing Klebsiella pneumoniae From Patients Without Ceftazidime-Avibactam Use History – A Multicenter Study in ChinaSemantic proximity Read ↗

Bloodstream infection caused by KPC-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam: epidemiology and genomic characterization.Semantic proximity Read ↗

Increased bla KPC Copy Number and OmpK35 and OmpK36 Porins Disruption Mediated Resistance to Imipenem/Relebactam and Meropenem/Vaborbactam in a KPC-Producing Klebsiella pneumoniae Clinical IsolateSemantic proximity Read ↗

Suboptimal ceftazidime-avibactam exposure drives sequential blaKPC mutations and intra-host coexistence of Klebsiella pneumoniae harboring distinct variants leading to persistent infection.Semantic proximity Read ↗

Cross-resistance to cefiderocol and ceftazidime–avibactam in KPC β-lactamase mutants and the inoculum effectSemantic proximity Read ↗

The Effect of β-Lactam Antibiotics on the Evolution of Ceftazidime/Avibactam and Cefiderocol Resistance in KPC-Producing Klebsiella pneumoniaeSemantic proximity Read ↗

Co-resistance to ceftazidime-avibactam and cefiderocol in clinical isolates producing KPC variantsSemantic proximity Read ↗

In Vitro Selection of Ceftazidime-Avibactam Resistance in Enterobacteriaceae with KPC-3 CarbapenemaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.